Imrecoxib: Advances in Pharmacology and Therapeutics
Yan-hong Wang,Ling-ling Zhu,Tian-lang Li,Quan Zhou
DOI: https://doi.org/10.2147/dddt.s464485
IF: 4.3188
2024-05-23
Drug Design Development and Therapy
Abstract:Yan-hong Wang, 1, &ast Ling-ling Zhu, 2, &ast Tian-lang Li, 3 Quan Zhou 1 1 Department of Pharmacy, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China; 2 VIP Geriatric Ward, Division of Nursing, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China; 3 Department of VIP Care and Geriatric Medicine, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Quan Zhou, Department of Pharmacy, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Jiefang Road No. 88, Shangcheng District, Hangzhou, 310009, Zhejiang Province, People's Republic of China, Email Tian-lang Li, Department of VIP Care and Geriatric Medicine, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China, Email Imrecoxib, a cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug (NSAID), was discovered via the balanced inhibition strategy of COX-1/COX-2. It is indicated for the relief of painful symptoms of osteoarthritis. There have been some pharmacological and therapeutic advances since the approval of imrecoxib in 2011. However, an update review in this aspect is not yet available. Relevant literature until January 2024 was identified by search of PubMed, Web of science, Embase and CNKI. From the perspective of efficacy, imrecoxib provides relief of osteoarthritis symptoms, and potential off-label use for treatment of idiopathic pulmonary fibrosis, perioperative pain, hand-foot syndrome, axial spondyloarthritis, COVID-19, cartilage injury, and malignancies such as lung and colon cancer. From a safety point of view, imrecoxib showed adverse effects common to NSAIDs; however, it has lower incidence of new-onset hypertension than other types of selective COX-2 inhibitors, less gastrointestinal toxicities than non-selective NSAIDs, weaker risk of drug interaction than celecoxib, and more suitable for elderly patients due to balanced inhibition of COX-1/COX-2. From a pharmacoeconomic perspective, imrecoxib is more cost-effective than celecoxib and diclofenac for osteoarthritis patients. With the deepening of the disease pathophysiology study of osteoarthritis, new therapeutic schemes and pharmacological mechanisms are constantly discovered. In the field of osteoarthritis treatment, mechanisms other than the analgesic and anti-inflammatory effects of COX-2 inhibitors are also being explored. Taken together, imrecoxib is a moderate selective COX-2 inhibitor with some advantages, and there would be more clinical applications and research opportunities in the future. Keywords: cyclooxygenase-2, efficacy, imrecoxib, non-steroidal anti-inflammatory drug, older adults, osteoarthritis, safety Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used in clinical practice to relieve pain and reduce inflammation. There are two main types of NSAIDs. Non-selective NSAIDs inhibit both cyclooxygenase (COX)-1 and COX-2, and exhibit common gastrointestinal (GI) side effects that may trouble the patients and limit their application. Selective NSAIDs, usually referred to COX-2 inhibitors, selective COX-2 inhibitors, or coxibs, have fewer GI side effects than non-selective NSAIDs, but long-term use of certain coxibs has been associated with cardiac side effects. 1 Imrecoxib is a selective COX-2 inhibitor launched in China in May 2011. 2 It is indicated for the relief of painful symptoms of osteoarthritis, and the usual dosage for adult patients is 100 mg twice daily. The cumulative duration of imrecoxib medication use was up to 24 weeks. Clinicians may not clearly know the difference between imrecoxib and other oral COX-2 inhibitors that are currently in use (ie, celecoxib, etoricoxib) and have been withdrawn from the market (ie, rofecoxib, lumiracoxib). Also, there have been some pharmacological and therapeutic advances since the approval of imrecoxib. We present an update narrative review, aiming at promoting rational medication use and facilitating related research. Potentially relevant journal papers with title or abstract containing imrecoxib until January 2024 was identified by performing searches in PubMed, Web of science core collection, Embase and CNKI. Two reviewers (WYH and ZLL) independently retrieved the literature and screened the relevant studies. If they have a disagreement over including or excluding an article, the third reviewer (QZ) was consulted. Documents were identified in PubMed (n=32), Web of Science C -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal